Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Sakamoto, Nagasaki, Japan.
Anticancer Res. 2011 Dec;31(12):4429-37.
The aim of this study was to clarify the relationship between vascular endothelial growth factor (VEGF) expression and clinicopathological factors in oral squamous cell carcinoma (OSCC). We also examined the correlation between the VEGF expression and the mammalian target of rapamycin (mTOR)-hypoxia inducible factor-1α (HIF-1α) pathway. Formalin-fixed paraffin-embedded tissues from 120 OSCC cases and 10 samples of normal mucosa were stained immunohistochemically for VEGF-A, VEGF-C, p-mTOR and HIF-1α proteins. VEGF-A and VEGF-C protein expression was detected in 76 out of 120 (63%) and 81 of 120 (67.5%) OSCCs, respectively, and their expression was significantly higher in primary OSCC than in normal oral mucosa. VEGF-A expression was significantly associated with the tumor stage and age. VEGF-C expression was significantly associated with the cancer cell invasion. The cases with combined p-mTOR+/HIF-1α(+)/VEGF-A(+) expression had a significantly higher tumor stage and invasion grade, and combined p-mTOR+/HIF-1α(+)/VEGF-C(+) expression was significantly associated with tumor stage, regional lymph node metastasis and invasion grade. In a survival analysis, no obvious correlation was observed with any of the immunohistochemical results. This study indicated that the mTOR-HIF-1α-VEGF pathway affects the progression of OSCC, and inhibition of this pathway may be useful for the treatment of OSCC.
本研究旨在阐明血管内皮生长因子 (VEGF) 表达与口腔鳞状细胞癌 (OSCC) 临床病理因素之间的关系。我们还研究了 VEGF 表达与哺乳动物雷帕霉素靶蛋白 (mTOR)-缺氧诱导因子-1α (HIF-1α) 通路之间的相关性。对 120 例 OSCC 病例和 10 例正常口腔黏膜的福尔马林固定石蜡包埋组织进行 VEGF-A、VEGF-C、p-mTOR 和 HIF-1α 蛋白的免疫组织化学染色。在 120 例 OSCC 中,76 例(63%)和 81 例(67.5%)检测到 VEGF-A 和 VEGF-C 蛋白表达,原发 OSCC 中的表达明显高于正常口腔黏膜。VEGF-A 表达与肿瘤分期和年龄显著相关。VEGF-C 表达与癌细胞浸润显著相关。p-mTOR+/HIF-1α(+)/VEGF-A(+) 表达的病例肿瘤分期和浸润分级显著较高,p-mTOR+/HIF-1α(+)/VEGF-C(+) 表达与肿瘤分期、区域淋巴结转移和浸润分级显著相关。在生存分析中,与任何免疫组化结果均无明显相关性。本研究表明,mTOR-HIF-1α-VEGF 通路影响 OSCC 的进展,抑制该通路可能对 OSCC 的治疗有用。